Close

Neuronetics Inc. (STIM) Prelim. Q3 Revenue Falls Short of Prior Guidance

Go back to Neuronetics Inc. (STIM) Prelim. Q3 Revenue Falls Short of Prior Guidance

Neuronetics (STIM) PT Lowered to $15 at Canaccord Genuity

October 13, 2021 8:06 AM EDT

Canaccord Genuity analyst William Plovanic lowered the price target on Neuronetics (NASDAQ: STIM) to $15.00 (from $21.00) while maintaining a Buy rating on weaker Q3 revenue.

The analyst commented, "Neuronetics announced preliminary Q3/21 revenue of ~$13.8M, missing our $15.0M estimate, and the companys guidance of $15M-$16M. Management commentary from the preannouncement indicated... More